AEON Biopharma, Inc. Total Assets
AEON Biopharma, Inc. total assets. Based on the latest financial reports, AEON Biopharma, Inc. (AEON) holds total assets worth $8.73 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AEON market cap for the company's overall valuation and market capitalisation.
Total Assets of AEON Biopharma, Inc. (2019–2024)
Total assets of AEON Biopharma, Inc. from 2019 to 2024. This chart illustrates how AEON Biopharma, Inc.'s total assets have evolved over time, based on quarterly financial data. See current stock price of AEON Biopharma, Inc. for real-time trading data and today's change.
AEON Biopharma, Inc. - Asset Composition Analysis
AEON Biopharma, Inc. Total Assets Breakdown (December 2024)
AEON Biopharma, Inc. total assets breakdown as of December 2024. AEON Biopharma, Inc.'s total assets of $8.73 Million consist of 50.6% current assets and 49.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how AEON Biopharma, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore AEON Biopharma, Inc. current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AEON Biopharma, Inc.'s current assets represent 50.6% of total assets in 2024, a decrease from 98.1% in 2019.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2024, down from 5.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
AEON Biopharma, Inc. Competitors by Total Assets
Key competitors of AEON Biopharma, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
AEON Biopharma, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.90 | 0.22 | 4.85 |
| Quick Ratio | 0.90 | 0.22 | 4.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-816.00K | $-8.36 Million | $16.18 Million |
AEON Biopharma, Inc. - Advanced Valuation Insights
This section examines the relationship between AEON Biopharma, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 2.88 |
| Asset Growth Rate (YoY) | -54.1% |
| Total Assets | $3.14 Million |
| Market Capitalization | $9.05 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values AEON Biopharma, Inc.'s assets at a significant premium (2.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: AEON Biopharma, Inc.'s assets decreased by 54.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AEON Biopharma, Inc. (2019–2024)
The table below shows the annual total assets of AEON Biopharma, Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.14 Million | -54.10% |
| 2023-12-31 | $6.84 Million | -36.49% |
| 2022-12-31 | $10.78 Million | +67.46% |
| 2021-12-31 | $6.44 Million | -69.66% |
| 2020-12-31 | $21.21 Million | -81.45% |
| 2019-12-31 | $114.35 Million | -- |
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more